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Various D2/3 receptor PET radioligands are sensitive to endogenous dopamine release in vivo. The Oc-
cupancy Model is generally used to interpret changes in binding observed in in vivo competition binding
studies; an Internalisation Hypothesis may also contribute to these changes in signal. Extension of in vivo
competition imaging to other receptor systems has been relatively unsuccessful. A greater understanding
of the cellular processes underlying signal changes following endogenous neurotransmitter release may
help translate this imaging paradigm to other receptor systems. To investigate the Internalisation Hy-
pothesis we assessed the effects of different cellular environments, representative of those experienced
by a receptor following agonist-induced internalisation, on the binding of three D2/3 PET ligands with
previously reported sensitivities to endogenous dopamine in vivo, namely [3H]spiperone, [3H]raclopride
and [3H]PhNO. Furthermore, we determined the contribution of each cellular compartment to total
striatal binding for these D2/3 ligands. These studies suggest that sensitivity to endogenous dopamine
release in vivo is related to a decrease in afﬁnity in the endosomal environment compared with those
found at the cell surface. In agreement with these ﬁndings we also demonstrate that ~25% of total striatal
binding for [3H]spiperone originates from sub-cellular, microsomal receptors, whereas for [3H]raclopride
and [3H]PhNO, this fraction is lower, representing ~14% and 17%, respectively. This pharmacological
approach is fully translatable to other receptor systems. Assessment of afﬁnity shifts in different cellular
compartments may play a crucial role for understanding if a radioligand is sensitive to endogenous
release in vivo, for not just the D2/3, but other receptor systems.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Positron emission tomography (PET) and single photon emis-
sion computerised tomography (SPECT) imaging studies are
frequently conducted in order to non-invasively investigate regu-
lation of dopamine D2/3 receptors (D2/3) in healthy and diseased
populations (Abi-Dargham, 2004 Volkow et al., 2007). As such, D2/3
receptor PET and SPECT studies have contributed vastly to our
understanding of dopaminergic neurotransmission in stimulant
misuse and schizophrenia (Laruelle, 1998; Abi-Dargham, 2004;armacology, Division of Brain
spital, Du Cane Road, London
uelch).
r Ltd. This is an open access articleVolkow et al., 2007; Martinez and Narendran, 2010). A variety of
D2/3 radioligands are sensitive to acute ﬂuctuations in dopamine
levels in vivo (Laruelle, 2000), where the Occupancy Model is
generally used to interpret the changes in binding observed.
However, temporal discrepancies between the dopamine surge
following treatment with compounds such as amphetamine and
the change in D2/3 PET signal have been identiﬁed (Laruelle et al.,
1997; Cardenas et al., 2004; Houston et al., 2004; Narendran
et al., 2007; Skinbjerg et al., 2010). Furthermore, translation of
endogenous release paradigms based on The Occupancy Model to
other neurotransmitter systems have been relatively unsuccessful,
suggesting that direct competition of radioligand by endogenous
neurotransmitter molecule might not sufﬁciently describe the data.
Agonist-induced internalisation is a cellular mechanism which
regulates secondary messenger signalling and functional receptor
density at the plasma membrane (Tsao et al., 2001). Typically,under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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domains by G-protein receptor kinases (GRK), the receptor-ligand
complex is trafﬁcked towards the endocytic machinery either for
lysosomal degradation or to be prepared for re-insertion into the
cell membrane. During this trafﬁcking the receptor-ligand complex
is exposed to a variety of ionic conditions, depending on its stage in
the internalisation pathway. Compared with the D1 receptor
(Dumartin et al., 1998; Martin-Negrier et al., 2006; Kong et al.,
2011), D2/3 receptor internalisation is less extensively characterised.
However D2/3 receptors have been shown to be present in the
microsomal and cytosolic compartments in the absence of phar-
macological stimulation using immunological based techniques
(Paspalas et al., 2006) and a fewgroups have demonstrated agonist-
induced internalisation of the D2 receptor in cell and tissue prep-
arations (Kim et al., 2001; Macey et al., 2004; Paspalas et al., 2006).
D3 receptor internalisation has also been observed following
dopamine stimulation in cell systems (Kim et al., 2001; Cho et al.,
2007).
An agonist-induced receptor internalisation model has been
proposed to contribute to the signal changes observed in endoge-
nous competition PET studies, known as the Internalisation Hy-
pothesis (Laruelle, 2000). Changes in receptor availability or afﬁnity
for a radioligand following internalisation may alter observed
Binding Potential (BP); since BP is proportional to Bmax/KD.
Following this proposal by Laruelle (2000), a number of reports
have been made in support of this Internalisation Hypothesis. Of
note, Skinbjerg et al. (2010) used an internalisation deﬁcient mouse
model, and demonstrated the binding proﬁles of both [11C]MNPA
and [18F]fallypride better matched the time course of dopamine
release following amphetamine in the absence of internalisation
(Skinbjerg et al., 2010). Additionally, Guo et al. (2010) have shown
the afﬁnity of various D2/3 ligands to be altered following
quinpirole-induced internalisation in cell systems (Guo et al., 2010).
More recently we have reported the ability of the selective sero-
tonin transporter protein (SERT) radioligand, [3H]DASB, to bind to
the SERT to be signiﬁcantly reduced in sub-cellular conditions
compared with membrane bound conditions utilising an in vitro
model (Quelch et al., 2012).
The effect of changing sodium concentration and pH on dopa-
mine receptor radioligand binding has been previously reported
(Hamblin and Creese, 1982; Sibley and Creese, 1983; Watanabe
et al., 1985; Neve, 1991; Sokoloff et al., 1992; Malmberg and
Mohell, 1995). However, to our knowledge, the effects of other
ions which also differ throughout the agonist-mediated internal-
isation pathway, on the binding parameters of widely used PET
radioligands, have not been investigated as extensively.
In general, the signal associated with any central nervous sys-
tem PET radioligand is assumed to originate mainly from mem-
brane bound target proteins. However, the contribution to the
overall PET signal via the protein target of interest in sub-cellular
compartments have not been reported with D2/3 receptor PET
radioligands. Therefore, any involvement of the target protein in
these sub-cellular compartments to the overall observed total PET
signal will greatly increase our understanding of the cellular
mechanisms involved in endogenous release studies for particular
radioligands.
The data presented in this manuscript therefore sought to
determine (1) how the agonist induced internalisation path-
way may affect the binding parameters of the D2/3 radioligands,
[3H]raclopride, [3H]PhNO and [3H]spiperone in tissue prepara-
tions using in vitro methods previously published for other PET
radioligands (Quelch et al., 2012), and (2) the full cellular
composition of the striatal PET signal for the D2/3 radioligands,
spiperone, PhNO and raclopride at baseline using an in vitro cell
fractionation system.2. Methods
2.1. Membrane preparation
2.1.1. Rat tissue
Male Sprague Dawley rats (~250 g) were used for dissection and isolation of
striatal tissue. Wet tissue was weighed and homogenised in 10weight/volume (w/
v) Sucrose buffer (0.32 mM Sucrose, 5 mM Tris HCl, 1 mM MgCl2 pH 7.4, 4 C) and
centrifuged at 32,000 g (20 min, 4 C). The supernatant was removed and the pellet
washed twice by centrifugation (32,000 g, 20 min, 4 C) in Tris buffer (50 mM Tris-
Base, 1 mMMgCl2, pH7.4, 4 C). The ﬁnal pellets were re-suspended in Tris buffer to
approximately 10 mg/ml.
2.1.2. Sub-cellular fractionation
The sub-cellular fractionation procedure was based on methods previously
presented (Laduron,1977; Sun et al., 2003). The constituents of the isolated fractions
are: P1¼ nuclear and cell debris fraction. P2¼ plasmamembrane andmitochondrial
pellet. P3 ¼ microsomal pellet diluted in endosomal buffer and S3 ¼ cytosolic
fraction.
The translation from rat to pig tissue was made based on data presented in
Supplementary Table 1, Supplementary Fig. 1. Rat and pig D2/3 radioligand receptor
binding parameters were shown to be altered in a similar manor following exposure
to the different cellular environments investigated in this manuscript i.e. lower
in vitro BP values in the endosomal environment compared with the extracellular,
driven by reductions in afﬁnity. Furthermore, use of pig striatum allowed for re-
ductions in animals numbers.
Striatal tissue (3 g) was isolated from each individual Danish Yorkshire Landrace
pig (n ¼ 3). Tissues were suspended in 10 w/v sucrose buffer and homogenised
using a teﬂon glass homogeniser (20 strokes, on ice). The crude homogenate was
centrifuged at a low speed (1000 g, 10 min, 4 C) to generate the P1. The supernatant
(S1) was set aside for further centrifugation. P1 was re-suspended in Tris buffer and
washed twice by centrifugation at (1000 g, 10 min, 4 C), with the resulting addi-
tional S1 supernatants added to the original supernatant (S1). The total S1 was
centrifuged at a higher speed (17,000 g, 20 min, 4 C) to generate P2. The super-
natant resulting from this spin (S2) was set aside for further centrifugation. P2 pellet
was re-suspended in Tris buffer and washed twice by centrifugation (32,000 g,
20 min, 4 C), with the resulting additional S2 supernatants added to the original
supernatant (S2). The total S2 was centrifuged (100,000 g, 90 min, 4 C) to generate
the P3. The supernatant from P3, S3, was collected as the cytosolic fraction of the
striatal cells. P2 was resuspended in Extracellular buffer (see below). P3 was
resuspended in endosomal buffer (see below). Samples of the cell fractions (250 ml of
each) were assessed for protein content and the remainder aliquoted and stored
at 80 C for use in subsequent radioligand binding studies.
2.2. Radioligand Binding assays
2.2.1. Saturation studies
Tissue samples (P2) generated from rat striatal membranes were diluted to
200 mg membrane protein/well in each of the three relevant physiological buffers,
previously reported by Quelch et al. 2012 (1) Extracellular (Extra ¼ 50 mM Tris HCl,
140mMNaCl, 5 mMKCl,1.5 mMMgCl2, 1.5 mMCaCl2, pH 7.4, 37 C); (2) Intracellular
(Intra¼ 50 mM Tris HCl, 10 mM NaCl, 140 mM KCl, 0.5 mMMgCl2, pH 7.0, 37 C) and
(3) Endosomal (Endo ¼ 20 mM MES, 10 mM NaCl, 140 mM KCl, 0.5 mM MgCl2,
0.003 mM CaCl2, pH 6.0, 37 C) (Quelch et al., 2012); concentrations are adapted
from Brinley (1980), Murphy et al. (1984), Gerasimenko et al. (1998), Gekle et al.
(1999), Grabe and Oster (2001), Alberts et al. (2002), Christensen et al. (2002),
Faundez and Hartzell (2004), Somjen (2004) and incubated (37 C) with a range
of radioligand concentrations ([3H]raclopride 0.003e30 nM, [3H]PhNO 0.003e10
and [3H]spiperone 0.003e10 nM). The speciﬁc binding component was determined
using haloperidol (1 mM). Assays were terminated via ﬁltration through Whatman
GF/B ﬁlters followed by 4  1 ml washes with ice-cold Wash buffer (50 mM Tris HCl,
pH 7.4, 4 C). Filters were transferred to scintillation vials and scintillation ﬂuid
(3ml/vial; Packard Ultima GoldMV) added and bound radioactivity determined on a
Packard Tricarb liquid scintillation counter. Whatman GF/B ﬁlters were pre-
incubated in polyethylenimine (PEI; 0.05%, 60 min) prior to ﬁltration.
2.2.2. Sub-cellular fraction studies
Radioligand binding studies were performed from three independent fraction-
ation procedures using pig striata. Fractions, P2, P3endo and S3, were diluted to
200 mg protein/well for addition to assay. These studies were performed using ﬁxed
concentrations of [3H]spiperone (5 nM), [3H]raclopride (20 nM) and [3H]PhNO
(5 nM). The speciﬁc binding component was determined using haloperidol (1 mM).
Following radioligand addition, assays were incubated at 37 C (60 min). Assays
were terminated via ﬁltration and radioactivity counted as described above.
2.2.3. Kinetic studies
Rat striatal P2 homogenates were thawed and diluted to the desired concen-
tration (200 mg membrane protein/well) in both extracellular and endosomal
buffers. For association experiments, [3H]spiperone (1 nM), [3H]raclopride (2 nM) or
[3H]PhNO (1 nM) were added at 22 time points between 0 and 100 min to wells
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[3H]spiperone (1 nM), [3H]raclopride (2 nM) or [3H](þ)PhNO (1 nM) were added to
the assay plate and allowed to associate at 37 C for 100 min. Following this, halo-
peridol (1 mM) was added to the plate at 22 time points between 101 and 200 min,
post-association in order to begin the dissociation. All time points were terminated
simultaneously via ﬁltration and radioactivity counted as described above.
2.3. Protein assay
Protein concentrations were determined by the colorimetric method using
bicinchoninic acid assay at 562 nm (Thermo Scientiﬁc Pierce BCA Protein Assay Kit)
(Smith et al., 1985).
2.4. Data analysis
All data were analysed using GraphPad Prism 5.0. One- and Two-way ANOVA
were performed using SigmaStat 3.0. Student's t-tests were performed using
GraphPad Prism 5.0. Bmax values in pmol/g tissue (nM) were generated according to
Equation (1) (where it is assumed that 1 ml of homogenised wet weight tissue is
equivalent to 1 g in weight). In vitro binding potentials (BP) were generated using
Equation (2). Relative Speciﬁc Activity (RSA) values were generated using Equation
(3) (Laduron, 1977). Kinetic parameters, kon and KD values were determined using
Equations (4) and (5), respectively.
Bmax in pmol/g tissue determination (where pmol/g is equivalent to nM);
B
0
max ¼
Bmax  Protein content
Mass tissue
(1)
Where B'max is the maximum number of binding sites expressed in pmol/g tissue
equivalent to nM; Bmax is the maximum number of binding sites expressed in fmol/
mg of protein; “Mass tissue” in assay in g/ml; and “Protein content” in mg/ml and it
is assumed that 1 g protein is the equivalent to 1 ml.
In vitro BP determination;
ivBP ¼ B
'
max
Kd
(2)
Where ivBP is the in vitro binding potential (unit less); B'max is the maximum number
of binding sites expressed in pmol/g tissue equivalent to nM and Kd is the equilib-
rium dissociation constant in nM.
Relative speciﬁc activity (RSA) determination;
RSA ¼ % Specific binding per fraction
% Protein per fraction
(3)
Where RSA is the relative speciﬁc activity in each fraction; “% Speciﬁc binding per
fraction” is the percentage of total speciﬁc binding of the radioligand in the fraction
and “% Protein per fraction” is the percentage of the total protein in the fraction.
kon determination;
kon ¼

kobs  koff

½radioligand (4)
Where kon is the rate constant of the association of radioligand and receptor in
M1 min1; kobs is the observed rate constant for the association of radioligand and
receptor in min1; koff is the rate constant for the dissociation of radioligand and
receptor in min1 and [radioligand] is the concentration of radioligand in M.
Kinetic KD determination;
Kd ¼
koff
kon
(5)
Where Kd is the equilibrium dissociation constant in M; koff is the rate constant for
the dissociation of radioligand and receptor in min1 and kon is the rate constant of
the association of radioligand and receptor in M1 min1.
3. Results
3.1. Cellular environments
3.1.1. Saturation and kinetic studies e [3H]raclopride and [3H]PhNO
For all KD and Bmax determinations plateaus were reached
within the concentration ranges tested. The data from all condi-
tions and radioligands tested were best ﬁt to a single site. In gen-
eral, changing the physiological environments had no effect on the
observed Bmax for either [3H]raclopride or [3H]PhNO (Table 1). A
signiﬁcant reduction in KD for both [3H]PhNO and [3H]raclopride
was observed in the endosomal condition compared with theextracellular condition (Table 1). Additionally, [3H]raclopride and
[3H]PhNO kinetic KD values obtained in the extracellular conditions
were comparable with those obtained from saturation studies
(Table 2). koff rates for [3H]raclopride, and accurate kob values for
[3H]PhNO were unable to be determined in the endosomal condi-
tion, with full inhibition of binding and association plateau not
being achieved after 6 h following assay initiation (Table 2).
3.1.2. Saturation and kinetic studies e [3H]spiperone
A signiﬁcant effect of cellular environment was observed for KD
values obtained with [3H]spiperone (Table 1), however the
magnitude of this change in KD was less than that compared with
[3H]raclopride or [3H]PhNO. The kinetic KD obtained for [3H]spi-
perone was slightly lower (non-signiﬁcant) than that determined
from saturation studies (Table 2). In addition, the kinetic KD
determined in the extracellular conditionwas comparable to that in
the endosomal condition. An increase in association rate was
observed in the extracellular compared to the endosomal envi-
ronment for [3H]spiperone; this was not signiﬁcant (Table 2).
3.1.3. Saturation and kinetic studies e in vitro BPs
In vivo PET data is generally reported in terms of binding
potential (BP f Bmax/Kd). In vitro BPs were generated using
Equation (2) (Table 1). As expected from the saturation KD values,
a signiﬁcant reduction in in vitro BP values were observed with
[3H]raclopride, [3H]PhNO and [3H]spiperone in the endosomal
environment compared to the extracellular (Table 1), therefore
the following trend for the reduction in ‘Percentage of Extra-
cellular in vitro BP’ in the endosomal condition was observed:
[3H]PhNO > [3H]raclopride > [3H]spiperone (Table 1).
3.2. Sub-cellular fractionation
The greatest amount of striatal cell protein was observed in the
cytosolic fraction (Table 3). Lower levels were observed in the
plasma membrane and microsomal fractions (Table 3).
For each of the three radioligands investigated, the majority of
“Percent Bound per Fraction” was observed in the P2 fraction
(~67e83%) with lower levels bound to the P3 fraction (~14e25%)
and much lower levels bound to the S3 fraction (~3e8%; Table 3).
No signiﬁcant differences in plasma membrane, microsomal or
cytosolic percentage bound per fraction were observed when
comparing the cellular distribution across the three radioligands
(Table 3).
When both “Percentage Bound per Fraction” and “Percentage
Total Protein per Fraction” are both taken into account i.e. using
Equation (3), relative speciﬁc activity (RSA) values are generated.
The total striatal homogenate RSA values for [3H]spiperone were
found to be signiﬁcantly greater than those obtained for both [3H]
raclopride and [3H]PhNO (Fig. 1A, Table 3). Similar to the distribu-
tion of “Percentage total homogenate Bound per Fraction”, RSA
distribution was highest in the P2-plasma membrane fraction for
all ligands (Table 3).
No signiﬁcant differences were observed between [3H]raclopr-
ide, [3H]PhNO and [3H]spiperone P2 and S3 RSA values. However a
signiﬁcantly greater RSA value was present in P3 fractions with [3H]
PhNO and [3H]spiperone when compared with [3H]raclopride
(Fig. 1B, Table 3). A representation of striatal tissue fraction binding
as a function of fraction protein content can be seen in Fig. 1C.
4. Discussion
We have sought to determine the effects of three physio-
logical environments reﬂective of the cellular compartments exper-
ienced by a receptor following agonist-induced internalisation,
Table 2
Kinetic values for radioligands in extracellular and endosomal conditions.
Radioligand and buffer koff (min1) kob (min1) kon (M1 min1) Kinetic KD (nM) Saturation KD (nM) Fold difference$
[3H]Raclopride
Extra 0.4 ± 0.02 1.1 ± 0.2 0.5 ± 0.3 1.1 ± 0.5 2.0 ± 0.2 1.8 ± 1.1
Endo ND 0.03 ± 0.01 ND / 9.5 ± 3.6 /
[3H]PhNO
Extra 0.1 ± 0.02 0.6 ± 1.6 0.4 ± 0.3 0.7 ± 0.1 0.6 ± 0.1 0.9 ± 0.1
Endo 0.1 ± 0.1 ND ND / 10.3 ± 2.7 /
[3H]Spiperone
Extra 0.1 ± 0.01 0.4 ± 0.2 0.4 ± 0.2 0.6 ± 0.5 0.1 ± 0.01 0.2 ± 0.02
Endo 0.1 ± 0.03 0.2 ± 0.02 0.1 ± 0.04 1.0 ± 0.5 0.4 ± 0.2 0.4 ± 0.4
koff (min1), kob (min1), kon (M1 min1), Kinetic KD (nM) and Saturation KD (nM)/Kinetic KD (nM) fold difference for [3H]raclopride (n ¼ 3 extra, n ¼ 5 endo), [3H](þ)PhNO
(n¼ 4 extra, n¼ 2 endo) and [3H]spiperone (n¼ 3 extra, n¼ 3 endo; all data are mean ± s.e.mean). $Represent Saturation KD/Kinetic KD. All data analysedwith GraphPad Prism
5.0 using single site exponential association and dissociation ﬁts.
Table 1
KD, Bmax and in vitro BP values for each radioligand in the three physiological environments.
Radioligand and buffer KD (nM) Bmax (fmol/mg protein) Bmax (pmol/g tissue) In vitro BP % of extra in vitro BPp
[3H]Raclopride
Extra 2.0 ± 0.2 368 ± 80 13.8 ± 0.8 6.9 ± 0.1 100
Intra 4.3 ± 0.8 381 ± 86 12.9 ± 0.7 3.2 ± 0.3 47
Endo 9.5 ± 3.6** 292 ± 68 9.1 ± 0.5 1.2 ± 0.3** 18
[3H]PhNO
Extra 0.6 ± 0.1 130 ± 21 7.2 ± 0.2 14.5 ± 4.1 100
Intra 0.3 ± 0.1 169 ± 32 8.2 ± 0.5 25.4 ± 5.7 174
Endo 10.3 ± 2.7** 103 ± 41 6.1 ± 1.6 0.6 ± 0.1** 4
[3H]Spiperone
Extra 0.1 ± 0.01 265 ± 39 15.2 ± 0.5 179.5 ± 28.1 100
Intra 0.1 ± 0.1 349 ± 35 18.6 ± 1.6 168.1 ± 10.9 93
Endo 0.4 ± 0.2* 278 ± 51 18.3 ± 1.9 68.43 ± 14.2* 38
KD (nM) and Bmax (fmol/mg protein and pmol/g tissue) and in vitro BP values for [3H]raclopride, [3H](þ)PhNO and [3H]spiperone in rat striatum (n¼ 4, mean ± s.e.mean) in the
three ionic environments (Extra, Intra and Endo). One-way ANOVAwith Tukey post-test were performed using SigmaStat 3.0. *p < 0.05 and **p < 0.01 represent comparison of
intracellular or endosomal to the extracellular condition.
ANOVA results. [3H]Raclopride, KD: F(3,20) ¼ 12.47, p < 0.07; Bmax: F(2,20) ¼ 3.40, p ¼ 0.053. [3H]PhNO, KD: F(2,21) ¼ 5.95, p < 0.009; Bmax: F(2,20) ¼ 1.30, p ¼ 0.03. [3H]
Spiperone, KD: F(2,22) ¼ 3.28, p < 0.057; Bmax: F(2,22) ¼ 2.76, p < 0.085.
Table 3
Sub-cellular fractionation data from pig striatal membranes.
Radioligand and
fraction
% Total protein
per fraction
% Bound
per fraction
Homogenate RSA
[3H]Raclopride
P2 28.9 ± 4.5 82.5 ± 7.4 2.0 ± 0.3
P3 15.6 ± 1.3 14.3 ± 7.5 0.9 ± 0.5
S3 55.5 ± 4.9 3.2 ± 1.8 0.1 ± 0.03
Total ¼ 3.0*
[3H]PhNO
P2 28.9 ± 4.5 79.6 ± 2.5 2.1 ± 0.3
P3 15.6 ± 1.3 17.3 ± 2.6 1.1 ± 0.1
S3 55.5 ± 4.9 3.2 ± 1.7 0.1 ± 0.03
Total ¼ 3.3**
[3H]Spiperone
P2 18.1 ± 1.3 67.2 ± 2.9 3.6 ± 0.1
P3 16.1 ± 2.7 24.5 ± 7.2 1.5 ± 0.2
S3 65.1 ± 4.0 8.3 ± 10.1 0.1 ± 0.2
Total ¼ 5.2
Percentage of total amount protein per fraction, Percentage of total amount of [3H]
raclopride [3H](þ)PhNO and [3H]spiperone bound to each fraction (P2, P3 and S3),
relative speciﬁc activity (RSA) and Percentage of total binding signal (where
100% ¼ P2 þ P3 þ S3) for [3H]raclopride, [3H](þ)PhNO and [3H]spiperone from pig
striatal membrane fractionation studies (n ¼ 3, mean ± s.e.mean). *p < 0.05 and
**p < 0.01 represent comparison of total homogenate RSA. Total homogenate RSA.
[3H]Raclopride and [3H[PhNO binding were performed on the same striatal ho-
mogenate fractionation preparations, [3H]spiperone binding was performed on a
separate set of striatal preparations.
ANOVA results F(2,5) ¼ 13.49, p ¼ 0.0097. P3 RSA ANOVA results: F(2,4) ¼ 13.55,
p ¼ 0.017.
D.R. Quelch et al. / Neuropharmacology 85 (2014) 305e313308on the binding parameters of the D2/3 radioligands [3H]raclopride,
[3H]PhNO and [3H]spiperone. The relative contribution of each of
these three cellular compartments (extracellular, intracellular and
endosomal) to the overall basal PET signal given by the PET ligands
raclopride, PhNO and spiperone have also been estimated. Using
in vitro radioligand binding, a reduction in afﬁnity was observed for
[3H]raclopride and [3H]PhNO in the endosomal compared with the
extracellular environment; two radioligands with known sensi-
tivity to endogenous release in vivo. Alterations in receptor kinetics
in the different cell conditions may underpin these changes in af-
ﬁnity. Afﬁnity shifts with changing cellular environment lead to a
reduction in in vitro BP generated for these radioligands, the
magnitude of which was related to the change in BP
following endogenous dopamine release observed previously
in vivo with these ligands. Notably, compared with [3H]raclopride
and [3H]PhNO, a smaller change in afﬁnity was observed in the
endosomal condition compared with the extracellular condition for
[3H]spiperone, a radioligand thought not to be sensitive to
endogenous dopamine release in vivo. These data suggest that
changes in receptor afﬁnity following dopamine release and sub-
sequent agonist-induced internalisation may contribute to re-
ductions in BP observed in vivo, since BP is proportional to Bmax/KD.
Using sub-cellular fractionationwe estimated that in the absence of
a pharmacological challenge, the majority (~67e~83%) of the total
signal associated with [3H]raclopride, [3H]PhNO and [3H]spiperone
would result from membrane bound D2/3 receptors. In agreement
with our saturation data we also demonstrate that ~25% of total
D.R. Quelch et al. / Neuropharmacology 85 (2014) 305e313 309striatal binding for [3H[spiperone originates from sub-cellular,
microsomal receptors, whereas for [3H]raclopride and [3H]PhNO,
this fraction is lower, representing ~14% and 17%, respectively. The
cytosolic fraction contributes negligibly to the overall PET signal.
4.1. Effect of physiological environments on the binding properties
of [3H]raclopride, [3H]PhNO and [3H]spiperone
Receptor availabilities (Bmax) and afﬁnity (KD) values for all three
radioligands were generated in the extracellular environment and
found to be comparable to those previously reported in the litera-
ture (Seeman et al., 2007; Cumming, 2011). In order to recreate the
cellular environments present at each of the sub-cellular and cell
surface compartments as accurately as possible, a variety of liter-
ature sources were consulted that have examined the ionic com-
positions of various cell compartments and organelles (Brinley,
1980; Murphy et al., 1984; Gerasimenko et al., 1998; Gekle et al.,
1999; Grabe and Oster, 2001; Alberts et al., 2002; Christensen
et al., 2002; Faundez and Hartzell, 2004; Somjen, 2004). These
cellular buffers have previously been used to investigate the effects
of serotonin transporter endocytosis and sub-cellular localisation
on the binding of [3H]DASB (Quelch et al., 2012). To further validate
the translation from the effects of the cellular buffers on surface
receptors in an endosomal condition to endosomal receptors
(found in the P3 fraction) we have performed P3 binding in both
extracellular and endosomal conditions. With [3H]raclopride, for
example, P3 binding is 1.98 fold higher in the extracellular condi-
tion (RSA ¼ 1.77) compared with when conducted in the endo-
somal condition (RSA ¼ 0.89). Interpolating from the saturation
binding curves conducted in P2 homogenates in different cellular
buffers at the radioligand concentration used in the fractionation
binding studies (20 nM for [3H]raclopride), the speciﬁc binding in
the extracellular condition is 1.95 fold greater in the extracellular
condition (331.4 fmol/mg) comparedwith the endosomal condition
(170.5 fmol/mgn). We consider these binding shifts very similar
and therefore assume these are representative of the afﬁnity shift
experienced by endosomally trafﬁcking receptors.
The effects of changing sodium levels on receptor afﬁnity for
benzamide ligands, e.g. raclopride, and butyrophenone ligands, e.g.
spiperone have previously been investigated (Stefanini et al., 1980;
Freedman et al., 1982; Neve, 1991; Neve et al., 1991; D'Souza and
Strange, 1995). However, the effects of these changing ionic con-
ditions have been less extensively investigated for the D3-prefer-
ring agonist ligand, [3H]PhNO. Additionally, the effect of changing
the ionic composition of not just sodium but also pH, calcium,
potassium, magnesium and chloride ions to concentrations repre-
sentative of those found in the extracellular, intracellular and
endosomal compartments on the speciﬁc binding of the three D2/3
ligands have also not been reported previously.
In agreement with the saturation data presented here, Neve
(1991) demonstrated a decrease in benzamide ([125I]epidepride),
but not butyrophenone ligand ([3H]spiperone), afﬁnity following a
reduction in assay pH and sodium concentration. Two amino-acid
sites within the D2 are thought to confer benzamide pH and so-
dium sensitivity with a pKa of 6e7, whereas one site with a pKa of
5.5e6.1 is thought to confer this sensitivity for butyrophenone li-
gands (D'Souza and Strange, 1995). Within our physiological
buffers, both amino-acids required for benzamide binding could be
ionised at pH6.0 within the endosomal condition leading to the
reduction in [3H]raclopride binding. This pH of 6.0 may not be
acidic enough to cause the ionisation of the single site required for
[3H]spiperone binding, which would account for [3H]spiperone
appearing less sensitive to the different conditions tested in this
study. [3H]PhNO was more sensitive to changes in ionic environ-
ment than the D2/3 receptor antagonist radioligands, suggestingthat the endosomal environment may be less favourable for D2high
receptor than for D2low receptor binding. Inclusion of magnesium
and calcium ions in assay buffers has been shown to increase af-
ﬁnity of agonist ligands such as NPA and apomorphine (Sibley and
Creese, 1983; Abolfathi and Di Paolo, 1991). However, no signiﬁcant
reduction in afﬁnity was observed from extracellular to intracel-
lular (where magnesium and calcium were both depleted
compared to the extracellular) but when, pH was further dropped
from 7.0 to 6.0 (and magnesium and calcium were still depleted),
[3H]PhNO afﬁnity was signiﬁcantly reduced. Therefore the dramatic
loss of afﬁnity observed by [3H]PhNO appears to be mainly pH
driven. Together, these data further support the idea that agonist
PET ligands may be preferential for use when trying to image
endogenous release in vivo since they would be expected to exhibit
a greater loss of receptor afﬁnity and hence a greater decrease in
in vivo BP following endogenous transmitter release and trans-
location to the endosomal compartment.
Guo et al. (2010) have demonstrated a similar afﬁnity shift
following quinpirole induced D2 receptor internalisation of
raclopride, PhNO and spiperone in D2short expressing cell systems.
Building upon these ﬁndings, we suggest that following internal-
isation of D2/3 receptors to endosomal vesicles, the decrease in af-
ﬁnity observed may be driven by alterations in receptor binding
kinetics. For both [3H]raclopride and [3H]PhNO, two ligands known
to be sensitive to endogenous release of dopamine in vivo, we show
incomplete equilibrium kinetics in the endosomal compartment
compared with that observed at the plasma membrane. Further-
more, no signiﬁcant changes in the kinetic parameters measured
were observed between extracellular and endosomal cellular envi-
ronments with [3H]spiperone. These data support, both ho-
mogenate binding studies and in vivo dosing data, which suggest
[3H]spiperone binding is less sensitive to changes in sodium and
hydrogen ion concentration and intracellular trapping of [3H]spi-
perone followingendocytosis of D2/3 receptors (Chugani et al.,1988).
Importantly, we report the change in in vitro BP from the extracel-
lular to the endosomal condition is consistent with the known
sensitivity to endogenous dopamine release previously observed
in vivo i.e. [11C/3H]PhNO > [11C/3H]raclopride > [11C/3H]spiperone
(Hartvig et al., 1997; Shotbolt et al., 2011). These ﬁndings suggest
that in addition to different pharmacological properties of radio-
ligands (i.e. antagonist versus agonist radioligands) contributing to
sensitivity to endogenous neurotransmitter release, a greater effect
of receptor internalisation on radioligand binding parameters may
also drive an increased vulnerability to signal changes observed
in vivo with [11C/3H]PhNO compared with [11C/3H]raclopride or
[11C/3H]spiperone. Investigating the sensitivity of other D2/3 radio-
ligand's (such as NPA, fallypride and FLB 457), to the different en-
vironments used in our assays therefore now warrants further
investigation.
4.2. Cellular composition of striatal binding for [3H]raclopride, [3H]
PhNO and [3H]spiperone
The cellular and sub-cellular distribution of dopamine receptors
have previously been described (Chugani et al., 1988; Yung et al.,
1995; Bloch et al., 2003; Sun et al., 2003; Voulalas et al., 2011).
We present relative speciﬁc activity values (RSA), which represent
binding as a function of fraction protein content (Laduron,1977). D2
expression has been observed previously in cytosolic fractions us-
ing semi-quantitative Western blot analysis (Voulalas et al., 2011)
and electron microscopy (Paspalas et al., 2006). D3 receptor cyto-
plasmic and intracellular vesicle localisation has also been noted
(Diaz et al., 2000). Together with the binding data from the cyto-
solic compartment (S3), this suggests that both D2 and D3 receptors
may be present in the cytoplasm but may not be in the correct
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Table 4
Prediction of alteration in total binding following D2/3 endocytosis.
Radioligand KD (nM) % Bound per fraction Fraction binding
capacity (% binding
per fraction/KD)
20% of surface receptors
endocytose e % binding/fractionV
Fraction binding capacity post-endocytosis
(% binding per fraction/KD)
[3H]Raclopride
Cell Surface 2.0 (extra) 82.5 (P2) 41.3 66.0 33.0
Microsomal 9.5 (endo) 14.3 (P3) 1.5 32.8 3.5
Cytosol 4.3 (intra) 3.2 (S3) 0.7 3.2 0.7
Total: 43.5 Total: 37.2 (14.5% reduction)
[3H]PhNO
Cell Surface 0.6 (extra) 79.6 (P2) 132.7 63.7 106.2
Microsomal 10.3 (endo) 17.3 (P3) 1.68 33.2 3.3
Cytosol 0.3 (intra) 3.2 (S3) 10.7 10.7 10.7
Total: 145.0 Total: 120 (17.2% reduction)
[3H]Spiperone
Cell Surface 0.1 (extra) 67.2 (P2) 672.1 53.8 538
Microsomal 0.4 (endo) 24.5 (P3) 81.7 37.0 126.3
Cytosol 0.1 (intra) 8.3 (S3) 21.5 8.3 21.5
Total: 775.2 Total: 685 (11.5% reduction)
Prediction of alteration in total binding following D2/3 endocytosis. VAssumes that 20% of surface, membrane bound receptors endocytose to the microsomal compartment,
and that no lysosomal trafﬁcking and degradation of existing receptors occurs.
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contributes very little to total the tissue binding as a consequence.
Despite the highest levels of binding emanating from the plasma
membrane fractions for all three radioligands, the ‘Percent Bound
Per Fraction’ obtained for P2 and P3 for [3H]raclopride, [3H](þ)
PhNO and [3H]spiperone suggests that a signiﬁcant proportion of
the signals observed in vivo could be due to subcellular, microsomal
binding. The RSA values for both [3H]spiperone and [3H]PhNO in
the microsomal fraction were greater than that observed for [3H]
raclopride. This may represent an increased abundance of D3 re-
ceptor in the sub-cellular compartments which would lead to in-
creases in [3H]PhNO binding in the microsomal compartments
compared with [3H]raclopride. Increased [3H]spiperone binding in
microsomal fractions maybe due to sequestered levels of 5HT2A
receptors. [3H]Spiperone has been shown to have signiﬁcant af-
ﬁnity at 5HT2A receptors (~0.5 nM in transfected HEK293 cells)
(Pritchett et al., 1988). Furthermore, the majority 5HT2A receptors
located on dendrites of rat ventral tegmental area dopaminergic
cells have been shown to be sub-cellularly located (Doherty and
Pickel, 2000).
In this manuscript we describe the cellular composition of total
striatal tissue binding with [3H]raclopride, [3H]PhNO and [3H]
spiperone. Laruelle (2012) recently proposed an updated D2 re-
ceptor model with reference to D2/3 PET imaging, whereby ~60% of
striatal D2/3 are conﬁgured in a high afﬁnity state and ~35% are
conﬁgured in a low afﬁnity state (based on studies comparing
agonist versus antagonist D2/3 PET ligands) (Laruelle, 2012). We
demonstrate here a population of receptors, similar in ‘Percent
Bound Per Fraction’ across all three radioligands that represents
D2/3 at the plasma membrane (~67e~83%). This population is
comparable in magnitude to that described by Laruelle (2012)
when combining both D2/3high/low but excluding a population of
extrasynaptic or internalised D2/3 receptors (~75% (Laruelle,
2012)). The studies presented here do not distinguish between
synaptic and extrasynaptic D2/3, however we propose that despiteFig. 1. A. Comparison of [3H]raclopride, [3H]PhNO and [3H]spiperone “Total Homogenate RSA
striatal membranes; n ¼ 3 for [3H]raclopride and [3H]PhNO; n ¼ 2 for [3H]spiperone (mean ±
*p < 0.05 and **p < 0.01 represent comparison of [3H]spiperone RSA to both [3H]raclopride an
spiperone. [3H]Raclopride and [3H]PhNO n ¼ 3; n ¼ 2 for [3H]spiperone (mean ± s.e.mean).
PhNO P3 RSA. C. Representation of homogenate binding as a function of cell protein. Relat
raclopride, [3H](þ)PhNO and [3H]spiperone from pig striatal sub-cellular fractionation; n ¼the similarities in proportions of membrane bound receptors
(comprising the majority of total striatal binding for all three
radioligands tested) the differences in their behaviours following
endogenous dopamine release in vivo will possibly be dependent
on their ability to bind D2/3 following internalisation. This is re-
ﬂected using both saturation studies conducted in different
cellular environments and sub-cellular fractionation studies where
for [3H]raclopride and [3H]PhNO, the microsomal fraction contri-
bution to total striatal binding (~14% and 17%, respectively) is
considerably smaller compared with that of [3H]spiperone's
(~25%). Sub-cellular fractionation following pharmacological
challenge remains to be conducted using the methodology
implemented in this manuscript. However, we demonstrate using
the percent bound per fraction for each radioligand and the af-
ﬁnity values for each ligand in each physiological buffer, the ex-
pected magnitude of signal change should a constant amount of
membrane D2/3 endocytose to the microsomal compartment (20%
internalisation is used an example, see Table 4). These data sug-
gest that following endocytosis, the total striatal binding capacity
for [3H]raclopride, [3H]PhNO and [3H]spiperone would be reduced
in the same rank order as that seen in vivo with these
ligands following administration of a dopamine releasing agent i.e.
[3H]PhNO (17.2%) > [3H]raclopride (14.5%) > [3H]spiperone (11.5%).
These data remain to be corroborated in a pharmacological chal-
lenge model using the methodology implemented here. We
believe this would be of beneﬁt to furthering our understanding of
the cellular mechanisms underpinning signal changes observed
in vivo not only with D2/3 receptors but, also other receptor radi-
oligands sensitive to change following endogenous neurotrans-
mitter release.
In summary, using in vitro radioligand binding studies, we have
demonstrated that a reduction in afﬁnity was observed for all li-
gands tested in the endosomal compared with the extracellular
environment. The magnitude of this afﬁnity shift with changing
cellular environment was related to the change in BP reportedvalues”. Total homogenate binding observed following sub-cellular fractionation of pig
s.e.mean). One-way ANOVAwith Tukey post-test were performed using SigmaStat 3.0.
d [3H]PhNO. B.Microsomal fraction RSA values with [3H]raclopride, [3H]PhNO and [3H]
*p < 0.05 represent comparison of [3H]raclopride P3 RSA with [3H]spiperone and [3H]
ive speciﬁc activity (RSA) versus percent total protein per fraction histogram for [3H]
3 for [3H]raclopride and [3H]PhNO; n ¼ 2 for [3H]spiperone (mean ± s.e.mean).
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PhNO displayed a much greater reduction in binding in the endo-
somal condition compared with [3H]spiperone, a radioligand
thought not to be sensitive to endogenous dopamine release in vivo.
Therefore, we suggest that assessment of these afﬁnity shifts pre-
dicts ligand sensitivity to endogenous dopamine release. Using
sub-cellular fractionation assays we have estimated that in the
absence of a pharmacological challenge, the majority (~67e~83%)
of the total signal associated with [3H]raclopride, [3H]PhNO and
[3H]spiperone would result from membrane bound D2/3 receptors;
with a signiﬁcant (~14e~25%) contribution being derived from
microsomal D2/3 receptors and the cytosolic fraction contributing
negligibly to the overall PET signal.
This novel approach for estimating the cellular composition of a
PET signal under basal conditions now warrants further use for
other receptor PET ligands. Determination of susceptibility to af-
ﬁnity shifts following receptor internalisation may be a crucial
radioligand characteristic for determining sensitivity to neuro-
transmitter release in vivo. As such, the data presented here may
help translate in vivo competition imaging techniques to neuro-
transmitter systems outside the D2/3. Translational approaches such
as this, allow for an enhanced understanding of the pharmacology
underlying the in vivo PET signals for multiple receptor systems,
from both endogenous transmitter release and exogenous chal-
lenge studies.
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